Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis

Sponsor
Frederic PRAT, MD, PhD (Other)
Overall Status
Recruiting
CT.gov ID
NCT04840537
Collaborator
(none)
150
1
2
48
3.1

Study Details

Study Description

Brief Summary

Biliary stenosis not associated with a mass is difficult to diagnose with certainty. The diagnosis is usually based on a first-line cytological study of biliary brushing, which allows a diagnosis in 30 to 50% of cases. In the event of negativity, it is then possible to perform a cholangioscopy in a second step, which allows better sensitivity by performing biopsies. Performing cholangioscopy from the start could potentially save time and avoid disturbances associated with intermediate biliary stenting.

The main objective is to compare two strategies for exploring indeterminate biliary stenosis (1st vs. 2nd line retrograde cholangioscopy) in terms of diagnostic performance. The secondary objectives are to compare the same two strategies in terms of effectiveness, side effects and cost-effectiveness.

The primary outcome measure is the diagnostic yield (performance) of the initial investigation of indeterminate biliary stenosis: cytological brushing followed by cholangioscopy in case of failure (control group) or cholangioscopy from the start (study group).

Condition or Disease Intervention/Treatment Phase
  • Procedure: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of Two Diagnostic Strategies in Indeterminate Biliary Stenosis: Exploration by Retrograde Cholangioscopy From the Outset or After Failure of Conventional Techniques
Actual Study Start Date :
Dec 26, 2018
Actual Primary Completion Date :
Dec 26, 2018
Anticipated Study Completion Date :
Dec 26, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: cytological brushing followed by cholangioscopy in case of failure

Procedure: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage

Experimental: cholangioscopy from the start

Procedure: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage

Outcome Measures

Primary Outcome Measures

  1. Diagnostic yield (performance) of the initial investigation of indeterminate biliary stenosis: cytological brushing followed by cholangioscopy in case of failure (control group) or cholangioscopy from the start (study group). [48 months]

    Diagnostic performance is expressed primarily by sensitivity for the diagnosis of malignancy.

Secondary Outcome Measures

  1. Specific rate of diagnosis with cholangioscopy by spyglass used in 1st or 2nd intention [48 months]

  2. Rate of adverse events related to diagnostic procedures in each of the 2 groups [48 months]

  3. Comparison of the costs of the 2 diagnostic strategies [48 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presence of intra- or extrahepatic biliary stenosis, involving the main bile ducts: common hepatic duct, right and left hepatic ducts

  • Presence of clinical jaundice and / or biological cholestasis (GGT> 3N)

  • Absence of visible mass near the biliary stenosis after initial morphological assessment by abdominal CT scan, MRI with biliary sequences.

  • Endoscopic ultrasound performed and not having allowed the acquisition of material of diagnostic interest by guided puncture of the lesion.

  • No history of ERCP in the 6 months preceding inclusion and no biliary prosthesis (plastic or metal) in place at the time of inclusion

  • Collegial validation of the need for a formal diagnosis of indeterminate biliary stenosis in order to guide therapeutic management

  • Patients aged 18 to 85

  • Patient who gave his consent to participate in the study

  • No contraindication to anesthesia (ASA 1, 2,3)

  • Patient affiliated to a social security scheme (beneficiary or beneficiary)

  • Absence of pregnancy and current contraception in women of childbearing age

Exclusion Criteria:
  • Presence of a manifest tissue mass in relation to the biliary stenosis on CT and / or MRI imaging.

  • Very strong presumption of the etiological diagnosis of biliary stenosis given the history (history, background): i.e. liver surgery, cholecystectomy, autoimmunity

  • History of ERCP and / or percutaneous biliary drainage in the 6 months preceding inclusion

  • Presence of a plastic or metal biliary prosthesis in place at the time of inclusion

  • History of cephalic duodeno-pancreatectomy or hepatico-jejunal anastomosis

  • Non-passable stenosis of the main bile duct

  • Severe coagulopathy, thrombocytopenia <75,000 G / L, treatment with clopidogrel cannot be interrupted even temporarily

  • Anesthetic contraindication (ASA 4)

  • Inability to obtain informed consent

  • person deprived of liberty

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Beaujon Clichy France 92110

Sponsors and Collaborators

  • Frederic PRAT, MD, PhD

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Frederic PRAT, MD, PhD, Principal Investagator, Medical Doctor, Hôpital Cochin
ClinicalTrials.gov Identifier:
NCT04840537
Other Study ID Numbers:
  • SFED 131
First Posted:
Apr 12, 2021
Last Update Posted:
Apr 12, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Frederic PRAT, MD, PhD, Principal Investagator, Medical Doctor, Hôpital Cochin
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2021